[go: up one dir, main page]

WO2010085699A3 - Mammalian piggybac transposon and methods of use - Google Patents

Mammalian piggybac transposon and methods of use Download PDF

Info

Publication number
WO2010085699A3
WO2010085699A3 PCT/US2010/021871 US2010021871W WO2010085699A3 WO 2010085699 A3 WO2010085699 A3 WO 2010085699A3 US 2010021871 W US2010021871 W US 2010021871W WO 2010085699 A3 WO2010085699 A3 WO 2010085699A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
mammalian piggybac
mammalian
gene
piggybac transposon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/021871
Other languages
French (fr)
Other versions
WO2010085699A2 (en
Inventor
Nancy Lynn Craig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of WO2010085699A2 publication Critical patent/WO2010085699A2/en
Publication of WO2010085699A3 publication Critical patent/WO2010085699A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides mammalian piggyBac transposons and transposases. In particular embodiments, the present inventors have identified hyperactive mammalian piggyBac variants. The mammalian piggyBac transposons and transposases can be used in gene transfer systems for stably introducing nucleic acids into the DNA of a cell. The gene transfer system can be used in methods, for example, but not limited to, gene therapy, insertional mutagenesis, or gene discovery.
PCT/US2010/021871 2009-01-23 2010-01-22 Mammalian piggybac transposon and methods of use Ceased WO2010085699A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14679809P 2009-01-23 2009-01-23
US61/146,798 2009-01-23

Publications (2)

Publication Number Publication Date
WO2010085699A2 WO2010085699A2 (en) 2010-07-29
WO2010085699A3 true WO2010085699A3 (en) 2011-03-03

Family

ID=42356410

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/021871 Ceased WO2010085699A2 (en) 2009-01-23 2010-01-22 Mammalian piggybac transposon and methods of use

Country Status (1)

Country Link
WO (1) WO2010085699A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2962885T3 (en) 2015-05-15 2024-03-21 Massachusetts Gen Hospital Tumor necrosis factor receptor superfamily antagonist antibodies
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
CA3033617A1 (en) 2015-08-11 2017-02-16 Anie Philip Peptidic tgf-beta antagonists
EP4049665B1 (en) 2016-03-15 2025-03-12 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
US10457683B2 (en) 2017-04-12 2019-10-29 Magenta Therapeutics Inc. Aryl hydrocarbon receptor antagonists and uses thereof
AU2018358241A1 (en) 2017-10-31 2020-05-07 Edigene Biotechnology, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
EP3703715A1 (en) 2017-10-31 2020-09-09 Magenta Therapeutics, Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
WO2019108932A1 (en) * 2017-11-30 2019-06-06 Haemalogix Pty. Ltd. Methods for expanding kappa myeloma antigen chimeric antigen receptors expressing cells
JP2021510150A (en) 2018-01-03 2021-04-15 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Compositions and Methods for Amplification of Hematopoietic Stem Cells and Progenitor Cells and Treatment of Hereditary Metabolic Disorders
CN112313339A (en) 2018-01-05 2021-02-02 渥太华医院研究所 Modified vaccinia vector
AU2019211465B2 (en) 2018-01-23 2022-07-21 Mount Spec Investments Pty Ltd Expression vector and method
IT201800004253A1 (en) 2018-04-05 2019-10-05 Compositions and methods for the treatment of hereditary dominant catecholaminergic polymorphic ventricular tachycardia.
JP2021536458A (en) 2018-09-04 2021-12-27 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. Aryl Hydrocarbon Receptor Antagonists and Usage
US12419913B2 (en) 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
JP2022521486A (en) * 2019-02-08 2022-04-08 ディーエヌエイ ツーポイント インコーポレイテッド Transposon-based modification of immune cells
CN113584083A (en) 2020-04-30 2021-11-02 深圳市深研生物科技有限公司 Producer and packaging cells for retroviral vectors and methods for making the same
JP2023525007A (en) * 2020-05-04 2023-06-14 サリオジェン セラピューティクス インコーポレイテッド Dislocation-based therapy
US12467917B2 (en) 2021-03-16 2025-11-11 California Institute Of Technology Reconstructing human early embryogenesis in vitro with pluripotent stem cells
EP4368719A4 (en) * 2021-07-09 2025-07-09 Neogentc Corp TRANSPOSON SYSTEM AND USES THEREOF
JP7693253B2 (en) * 2021-07-09 2025-06-17 ネオジェンティーシ― コーポレーション Transposon systems and their uses
AU2022343729A1 (en) 2021-09-09 2024-03-21 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
US20250051735A1 (en) 2021-12-22 2025-02-13 Vanderbilt University Next generation transpososomes
US20250099588A1 (en) 2022-01-28 2025-03-27 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
CA3267488A1 (en) 2022-09-16 2024-03-21 King S College London COMPOSITIONS AND METHODS OF TREATMENT OF NEUROLOGICAL DISEASES
CN116949092A (en) * 2022-09-21 2023-10-27 上海吉量医药工程有限公司 Transposon system and application thereof
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
CN120752337A (en) 2022-12-14 2025-10-03 伦敦王室学院 Compositions and methods for treating neurological disorders
WO2024161022A2 (en) 2023-02-03 2024-08-08 King's College London Compositions and methods for treating neurological diseases
KR20250141243A (en) 2023-02-06 2025-09-26 블루록 테라퓨틱스 엘피 Degron fusion proteins and methods for producing and using the same
WO2024229386A1 (en) * 2023-05-04 2024-11-07 Saliogen Therapeutics, Inc. Myotis lucifugus transposase engineering
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2025126153A2 (en) 2023-12-14 2025-06-19 Aviadobio Ltd. Compositions and methods for treating sod1-mediated neurological diseases
CN119824018B (en) * 2025-01-10 2025-10-10 华中农业大学 MITE transposon for regulating and controlling content of tea tree sulfo metabolites and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1465993A2 (en) * 2002-01-09 2004-10-13 Minos Biosystems Limited Inducible transposition in transgenic organism using transposon vector
US20060210977A1 (en) * 2002-07-24 2006-09-21 Kaminski Joseph M Transposon-based vectors and methods of nucleic acid integration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1465993A2 (en) * 2002-01-09 2004-10-13 Minos Biosystems Limited Inducible transposition in transgenic organism using transposon vector
US20060210977A1 (en) * 2002-07-24 2006-09-21 Kaminski Joseph M Transposon-based vectors and methods of nucleic acid integration

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CADINANOS, J. ET AL.: "Generation of an inducible and optimized piggyBac transposon system", NUCLEIC ACID RESEARCH, vol. 35, no. 12, 2007, XP055026860, DOI: doi:10.1093/nar/gkm446 *
CHIUNG, S. ET AL.: "piggyBac is a flexible and highly active transposon as compared to Sleeping Beauty, Tol2, and Mos1 in mammalian cells", PNAS, vol. 103, no. 41, 10 October 2006 (2006-10-10), pages 15008 - 15013, XP008157406, DOI: doi:10.1073/pnas.0337370100 *
DING, S. ET AL.: "Efficient Transposition of the piggyBac (PB) Transposon in Mammalian Cells and Mice", CELL, vol. 122, 12 August 2005 (2005-08-12), pages 473 - 483, XP002656530, DOI: doi:10.1016/j.cell.2005.07.013 *
RAY, D. ET AL.: "Multiple waves of recent DNA transposon activity in the bat, Myotis lucifugus", GENOME RESEARCH, vol. 18, 13 March 2008 (2008-03-13), pages 717 - 728, XP055026850, DOI: doi:10.1101/gr.071886.107 *
TOSHIKI, T. ET AL.: "Germline transformation of the silkworm Bombyx mori L. using a piggyBac transposon-derived vector", NATURE BIOTECHNOLOGY, vol. 18, no. 1, 2000, pages 81 - 84, XP002945821, DOI: doi:10.1038/71978 *
WANG, W. ET AL.: "Chromosomal transposition of PiggyBac in mouse embryonic stem cells", PNAS, vol. 105, no. 27, July 2008 (2008-07-01), pages 9290 - 9295, XP055026857, DOI: doi:10.1073/pnas.0801017105 *

Also Published As

Publication number Publication date
WO2010085699A2 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
WO2010085699A3 (en) Mammalian piggybac transposon and methods of use
WO2010099301A3 (en) Piggybac transposon variants and methods of use
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
GEP20217251B (en) Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
EP4375373A3 (en) Cas variants for gene editing
WO2012092515A9 (en) Methods, systems, and computer readable media for nucleic acid sequencing
WO2012027572A3 (en) Methods for nucleic acid capture and sequencing
EP4282970A3 (en) Rna-guided human genome engineering
MX351043B (en) Methods for genomic modification.
WO2010048417A3 (en) Perfusion bioreactors, cell culture systems, and methods for production of cells and cell-derived products
WO2013023176A3 (en) Polymerase compositions, methods of making and using same
WO2015157579A3 (en) Enhanced nucleic acid constructs for eukaryotic gene expression
WO2010088517A8 (en) Methods and systems for purifying transferring and/or manipulating nucleic acids
WO2013154999A3 (en) Method of preparation of nanopore and uses thereof
WO2015160895A3 (en) Modified transposases for improved insertion sequence bias and increased dna input tolerance
HK1211260A1 (en) Method and kit for nucleic acid sequencing
WO2009117439A3 (en) Combined chemical and genetic approaches for generation of induced pluripotent stem cells
MX2014014650A (en) Supercoiled minivectors as a tool for dna repair, alteration and replacement.
WO2012134602A3 (en) Methods and systems for sequencing long nucleic acids
WO2009120374A3 (en) Methods and compositions for nucleic acid sample preparation
MX2021000211A (en) Methods and products for transfecting cells.
WO2012122318A3 (en) Methods for transfecting cells with nucleic acids
WO2008118212A3 (en) In vivo delivery of double stranded rna to a target cell
LU91864B1 (en) Method and kit for the isolation of genomic DNA, RNA, proteins and metabolites from a single biological sample
WO2013050881A3 (en) Direct nucleic acid analysis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10733942

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10733942

Country of ref document: EP

Kind code of ref document: A2